Literature DB >> 6566601

Muramyl dipeptide is a powerful potentiator of the antitumor action of various tumor-necrotizing agents.

N Bloksma, F M Hofhuis, J M Willers.   

Abstract

The previously observed potentiation of necrosis and regression of solid immunogenic Meth A sarcoma transplants in mice after IV administration of endotoxin by addition of muramyl dipeptide (MDP) in saline was investigated further by varying time and route of administration of both agents. Equal potentiation was observed when MDP was administered 4 h before or after endotoxin, but administration 48 h or 24 h before or 24 h after endotoxin had no effect. Simultaneous administration of both agents enhanced tumor damage considerably, regardless of the route of administration of either agent. A strong potentiation of necrosis and regression was also observed upon addition of MDP to concanavalin A, poly I:C or poly A:U and, to a lesser degree, to a radio-detoxified endotoxin, purified L cell interferon, or Propionibacterium acnes. No consistent relationship could be seen between the degree of potentiation of necrosis and of regression. It was suggested that distinct mechanisms underlie the augmenting action of MDP on necrosis and regression and that enhanced production and/or action of vasoactive agents might play a role in the potentiation of necrosis. Whether the capacity of MDP to stimulate specific and nonspecific immune defense is involved in the enhancement of tumor regression remains uncertain at present.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6566601     DOI: 10.1007/bf00205479

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  Rapid appearance of histamine hypersensitivity in mice by minute dose of endotoxins.

Authors:  K Kuratsuka; R Homma; Y Shimazaki; I Funasaka
Journal:  Experientia       Date:  1975-02-15

Review 2.  Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents.

Authors:  L Chedid; F Audibert; A G Johnson
Journal:  Prog Allergy       Date:  1978

3.  Interactions of radio-detoxified Escherichia coli endotoxin preparations with the complement system.

Authors:  G Füst; L Bertók; S Juhász-Nagy
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

Review 4.  Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.

Authors:  L Chedid; C Carelli; F Audibert
Journal:  J Reticuloendothel Soc       Date:  1979-12

5.  Stimulation of the reticuloendothelial system of mice by muramyl dipeptide.

Authors:  A Tanaka; S Nagao; R Nagao; S Kotani; T Shiba; S Kusumoto
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

6.  Genetic influences on the adjuvanticity of muramyl dipeptide in vivo.

Authors:  M J Staruch; D D Wood
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

7.  Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo.

Authors:  N Bloksma; C F Kuper; F M Hofhuis; B Benaissa-Trouw; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer.

Authors:  J Lacour; F Lacour; A Spira; M Michelson; J Y Petit; G Delage; D Sarrazin; G Contesso; J Viguier
Journal:  Lancet       Date:  1980-07-26       Impact factor: 79.321

9.  Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.

Authors:  L A Chedid; M A Parant; F M Audibert; G J Riveau; F J Parant; E Lederer; J P Choay; P L Lefrancier
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

10.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  5 in total

1.  Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity.

Authors:  P A van de Wiel; A van der Pijl; N Bloksma
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Anti-neoplastic and immunomodulatory potency of co-treatment based on bovine lactoferrin and/or muramyl dipeptide in tumor-bearing mice.

Authors:  Hany M Ibrahim; Azza H Mohamed; Mohamed L Salem; Gamalat Y Osman; Dalia S Morsi
Journal:  Toxicol Res (Camb)       Date:  2020-04-24       Impact factor: 3.524

3.  Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin.

Authors:  N Bloksma; F M Hofhuis; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A:U against solid Meth A tumors in mice.

Authors:  N Bloksma; F M Hofhuis
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Effect of tumour necrosis factor and lipid A on functional and structural vascular volume in solid murine tumours.

Authors:  P A van de Weil; G J Bouma; A van der Pijl; E S Weitenberg; A W Lam; N Bloksma
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.